Known targets — ChEMBL curated mechanism
ACHECHKACHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGHRH2OPRM1
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 2/20 | 0.41 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.41 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.39 |
| ▸ | CHRNA10 | Q9GZZ6 | 2/20 | 0.39 |
| ▸ | CHRNA9 | Q9UGM1 | 2/20 | 0.39 |
| ▸ | GGPS1 | O95749 | 3/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | APAF1 | O14727 | 1/20 | 0.35 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.35 |
| ▸ | XBP1 | P17861 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | BLM | P54132 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.34 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13334308 | 0.99 | FFAR1 (0.42) | FFAR1FFAR4CHRNA7CHRNA10CHRNA9 | |
| Bromide SCHEMBL3313350 | 0.90 | CHRNA7 (0.41) | FFAR1FFAR4CHRNA7CHRNA10CHRNA9 | |
| SCHEMBL13334128 | 0.88 | FFAR1 (0.41) | FFAR1FFAR4CHRNA7CHRNA10CHRNA9 | |
| Bromide SCHEMBL3315760 | 0.85 | LMNA (0.46) | FFAR1FFAR4CHRNA7CHRNA10CHRNA9 | |
| SCHEMBL13334111 | 0.83 | KDM4E (0.47) | FFAR1FFAR4CHRNA7CHRNA10CHRNA9 | |
| Bromide SCHEMBL3310352 | 0.83 | HDAC1 (0.49) | CHRNA7CHRNA10CHRNA9GGPS1LMNA | |
| SCHEMBL13361702 | 0.83 | GGPS1 (0.46) | CHRNA7CHRNA10CHRNA9GGPS1LMNA | |
| SCHEMBL13334127 | 0.82 | FFAR1 (0.44) | FFAR1FFAR4LMNASMN1; SMN2USP2 | |
| SCHEMBL13334112 | 0.81 | HDAC1 (0.50) | CHRNA7CHRNA10CHRNA9GGPS1LMNA | |
| Bromide SCHEMBL3318547 | 0.80 | CHRNA7 (0.61) | FFAR1FFAR4CHRNA7CHRNA10CHRNA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140371266-A1 | Mono Quaternary Ammonium Salts and Methods for Modulating Neuronal Nicotinic Acetylcholine Receptors | UNIV KENTUCKY RES FOUND (US) | 2014-12-18 | — | — | US | claimed |
| US-8846937-B2 | Mono quaternary ammonium salts and methods for modulating neuronal nicotinic acetylcholine receptors | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 2014-09-30 | — | — | US | claimed |
| US-20100113511-A1 | Mono Quaternary Ammonium Salts and Methods for Modulating Neuronal Nicotinic Acetylcholine Receptors | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 2010-05-06 | — | — | US | claimed |
| WO-2007149392-A1 | MONO QUATERNARY AMMONIUM SALTS AND METHODS FOR MODULATING NEURONAL NICOTINIC ACETYLCHOLINE RECEPTORS | UNIVERSITY OF KENTUCKY (US) | 2007-12-27 | — | — | WO | claimed |
| US-9550753-B2 | Mono quaternary ammonium salts and methods for modulating neuronal nicotinic acetylcholine receptors | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 2017-01-24 | — | — | US | disclosed |
| US-20140371266-A1 | Mono Quaternary Ammonium Salts and Methods for Modulating Neuronal Nicotinic Acetylcholine Receptors | UNIV KENTUCKY RES FOUND (US) | 2014-12-18 | — | — | US | disclosed |
| US-8846937-B2 | Mono quaternary ammonium salts and methods for modulating neuronal nicotinic acetylcholine receptors | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 2014-09-30 | — | — | US | disclosed |
| US-20100113511-A1 | Mono Quaternary Ammonium Salts and Methods for Modulating Neuronal Nicotinic Acetylcholine Receptors | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 2010-05-06 | — | — | US | disclosed |
| WO-2007149392-A1 | MONO QUATERNARY AMMONIUM SALTS AND METHODS FOR MODULATING NEURONAL NICOTINIC ACETYLCHOLINE RECEPTORS | UNIVERSITY OF KENTUCKY (US) | 2007-12-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113511-A1 | Mono Quaternary Ammonium Salts and Methods for Modulating Neuronal Nicotinic Acetylcholine Receptors | CHRNA2, CHRNA4, CHRNA5 | FFAR1 677/4885FFAR4 988/4885CHRNA7 8/4885 |
| US-20140371266-A1 | Mono Quaternary Ammonium Salts and Methods for Modulating Neuronal Nicotinic Acetylcholine Receptors | CHRNA2, CHRNA4, CHRNA5 | FFAR1 652/4885FFAR4 953/4885CHRNA7 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.